Compare IDEXX Laboratories, Inc. (IDXX) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Rocket Lab USA Inc — how do they compare? IDEXX Laboratories, Inc. trades at $557.02 (market cap $44.48B), while Rocket Lab USA Inc trades at $68.16 (market cap $41.08B). The key difference: IDEXX Laboratories, Inc. and Rocket Lab USA Inc are close in size by market cap, and Rocket Lab USA Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | RKLB | |
|---|---|---|
Market Cap | $44.48B | $41.08B |
Sector | Health | Technology |
52-Week High | $766.68 | $150.23 |
52-Week Low | $520.87 | $39.48 |
Enterprise Value | $45.38B | $39.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Rocket Lab (RKLB) trades at $65.74, down 2.78% on the day, reflecting a bearish technical trend with support at $63. The company shows strong revenue growth with $601.80M in 2025 but remains unprofitable with a net loss of $198.21M. Recent news highlights competition with SpaceX and a potential catalyst from the Neutron rocket's development. Analyst consensus is overwhelmingly bullish with a $116.90 price target, though technical indicators signal near-term caution.
The outlook for RKLB hinges on execution of its growth strategy and path to profitability. Investment opportunity lies in its expanding launch contracts and competitive positioning in the space sector. Key risks include persistent cash burn, intense competition, and reliance on successful Neutron launches. Investors should weigh strong analyst optimism against fundamental challenges and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
